Rapid health technology assessment of lorlatinib in the treatment of non-small cell lung cancer
- VernacularTitle:洛拉替尼治疗非小细胞肺癌的快速卫生技术评估
- Author:
Yuqi SHANG
1
;
Hao GUO
2
;
Huiduo WANG
1
Author Information
1. School of Pharmacy，Baotou Medical College，Inner Mongolia University of Science and Technology，Inner Mongolia Baotou 014040，China
2. Dept. of Pharmacy，Inner Mongolia Autonomous Region People’s Hospital，Hohhot 010017，China
- Publication Type:Journal Article
- Keywords:
lorlatinib;
non-small cell lung cancer;
rapid health technology assessment;
effectiveness;
safety;
economy
- From:
China Pharmacy
2024;35(15):1812-1817
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE To evaluate the effectiveness， safety and economy of lorlatinib in the treatment of non-small cell lung cancer（NSCLC）， and provide evidence-based reference for the introduction of new drugs in hospitals and clinical medication decisions. METHODS Retrieved from PubMed， Embase， Cochrane Library， Epistemonikos， CNKI， VIP， Wanfang data， SinoMed databases and The International Network of Agencies for Health Technology Assessment （INAHTA）， the results of the included studies were descriptively analyzed after literature screening， data extraction and quality evaluation. RESULTS A total of 19 literature were included， involving 13 system assessment （SR）/meta-analyses and 6 pharmacoeconomic reviews. Compared with the patients who received other anaplastic lymphoma kinases （ALK）-tyrosine kinase inhibitor（TKI）（such as crizotinib， brigatinib， alectinib， ensartinib， and ceritinib）， those using lorlatinib obtained best progression-free survival （PFS）. However， in the Asian population， lorlatinib did not show a significant advantage in prolonging PFS， compared to ensartinib， low-dose alectinib， and brigatinib. In terms of objective remission rate， lorlatinib and low-dose alectinib showed significant advantages over other ALK- TKI. At the same time， alectinib had the best overall survival. In terms of safety， lorlatinib possessed a poor safety profile with a high incidence of grade 3 or higher adverse events. Existing economic studies showed that lorlatinib brought health benefits to first- line treatment of patients with ALK-positive advanced NSCLC at the same time as higher treatment costs. CONCLUSIONS Lorlatinib has good efficacy in the treatment of NSCLC， but its safety and economy need to be studied.
